HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- COVID-19 a ‘real wake-up call’ in how cancer clinical trials are conducted John DeRosier
-
- Screwing up cancer care Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- Translating advances in molecular oncology to the bedside Wen-I (Wendy) Chang, MD
- Cancer drugs’ targeted, anti-inflammatory effects support repurposing for COVID-19 Jai N. Patel, PharmD, BCOP, CPP
- ‘A call to arms’: Addressing the undertreatment of advanced bladder cancer Jennifer Byrne
- Adjuvant immunotherapy extends OS for certain patients with stage III melanoma Jennifer R. Southall
- Black patients less represented in pharmaceutical-led vs. NCI-sponsored cancer trials Jennifer R. Southall
- HSCT with total body irradiation vs. chemotherapy-based conditioning improves ALL outcomes John DeRosier
- Low-dose radiation after transoral resection effective in HPV-related oropharynx cancer John DeRosier
-
- Avelumab safe, effective for treatment of gestational trophoblastic tumors John DeRosier
- Off-the-shelf CAR-T regimen safe for advanced lymphoma Drew Amorosi
- Pyrotinib-capecitabine combination improves outcomes in breast cancer subset Mark Leiser
- Treatment with immune checkpoint inhibitors may lead to more severe COVID-19 illness John DeRosier
- Subcutaneous daratumumab noninferior to IV formulation, more tolerable for advanced multiple myeloma Jennifer R. Southall
- Escalated hydroxyurea dosing more effective for Ugandan children with sickle cell disease John DeRosier
- FDA approves Keytruda for cutaneous squamous cell carcinoma
- FDA grants fast track status to Betalutin for marginal zone lymphoma
-